{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:07:31Z","timestamp":1790352451714,"version":"4.1.0"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Oncolytic viruses (OVs) selectively replicate within tumors, directly killing cancer cells and promoting a systemic immune response by releasing tumor antigens. These features make OVs a promising approach in tumor immunotherapy, offering targeted treatment with fewer side effects. Despite these advantages, OVs are primarily administered via intratumoral injection, limiting their effectiveness for advanced, systemic cancers. Among OVs, oncolytic adenoviruses (oAdVs) are the most widely studied due to their well-understood gene regulation, safety, and stability. In this study, a modified oAdV vector, pDC316-oAd-SA, was engineered to express the SIRP\u03b1-mIgG1Fc gene, designed to remodel tumor-associated macrophages (TAMs) and enhance anti-tumor immunity. This vector, along with a control virus (Ad-ON), was evaluated both <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. The modified oAd-SA significantly improved macrophage phagocytosis and showed superior tumor regression in murine models. Additionally, while both oAdVs increased T cell infiltration in the tumor microenvironment, oAd-SA specifically enhanced T cell immune function. The study also revealed that oAdVs modulate TAMs differently across tumor types, with oAd-SA therapy particularly increasing TAM phagocytosis and promoting an anti-tumor response.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1513555","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T06:57:38Z","timestamp":1740466658000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Expression of SIRP\u03b1-Fc by oncolytic virus enhances antitumor efficacy through tumor microenvironment reprogramming"],"prefix":"10.3389","volume":"16","author":[{"given":"Qingzhe","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongheng","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongbing","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anliang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/713803696","article-title":"Vesicular stomatitis virus (Vsv) therapy of tumors","volume":"50","author":"Balachandran","year":"2000","journal-title":"IUBMB Life"},{"key":"B2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1158\/2326-6066.Cir-14-0015","article-title":"Oncolytic viruses and their application to cancer immunotherapy","volume":"2","author":"Chiocca","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: A new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: A new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discovery"},{"key":"B5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40425-018-0458-z","article-title":"Oncolytic virus immunotherapy: future prospects for oncology","volume":"6","author":"Raja","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/77558","article-title":"Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus","volume":"6","author":"Stojdl","year":"2000","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/77283","article-title":"Replicative adenoviruses for cancer therapy","volume":"18","author":"Alemany","year":"2000","journal-title":"Nat Biotechnol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1089\/10430349950017725","article-title":"A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma","volume":"10","author":"Hallenbeck","year":"1999","journal-title":"Hum Gene Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.ymthe.2020.01.003","article-title":"Immune modulation by telomerase-specific oncolytic adenovirus synergistically enhances antitumor efficacy with anti-pd1 antibody","volume":"28","author":"Kanaya","year":"2020","journal-title":"Mol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-14-0220-t","article-title":"Adenovirus improves the efficacy of adoptive T-cell therapy by recruiting immune cells to and promoting their activity at the tumor","volume":"3","author":"T\u00e4htinen","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.266","article-title":"Current issues and future directions of oncolytic adenoviruses","volume":"18","author":"Yamamoto","year":"2010","journal-title":"Mol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0736","article-title":"Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress","volume":"4","author":"Liu","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-09-3567","article-title":"Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients","volume":"70","author":"Cerullo","year":"2010","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-16-1708","article-title":"Oncolytic adenoviral delivery of an egfr-targeting T-cell engager improves antitumor efficacy","volume":"77","author":"Fajardo","year":"2017","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.79","article-title":"Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth","volume":"18","author":"Guedan","year":"2010","journal-title":"Mol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2017.08.035","article-title":"Synergistic antitumor effect mediated by a paclitaxel-conjugated polymeric micelle-coated oncolytic adenovirus","volume":"145","author":"Kasala","year":"2017","journal-title":"Biomaterials"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-10-2333","article-title":"Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery","volume":"70","author":"Kuroda","year":"2010","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1189\/jlb.4RI1216-516R","article-title":"Engineering macrophages to eat cancer: from \"Marker of self\" Cd47 and phagocytosis to differentiation","volume":"102","author":"Alvey","year":"2017","journal-title":"J Leukoc Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","article-title":"The interaction between signal regulatory protein alpha (Sirp\u03b1) and cd47: structure, function, and therapeutic target","volume":"32","author":"Barclay","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40820-021-00647-x","article-title":"Time-programmed delivery of sorafenib and anti-cd47 antibody via a double-layer-gel matrix for postsurgical treatment of breast cancer","volume":"13","author":"Huang","year":"2021","journal-title":"Nanomicro Lett"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12527","article-title":"The cd47-sirp\u03b1 Signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol Rev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.tcb.2008.12.001","article-title":"Functions and molecular mechanisms of the cd47-sirpalpha signalling pathway","volume":"19","author":"Matozaki","year":"2009","journal-title":"Trends Cell Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-14-2520","article-title":"Molecular pathways: activating T cells after cancer cell phagocytosis from blockade of cd47 \"Don't eat me\" Signals","volume":"21","author":"McCracken","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.02018","article-title":"First-in-human, first-in-class phase I trial of the anti-cd47 antibody hu5f9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s40425-019-0772-0","article-title":"Functional characterization of the selective pan-allele anti-sirp\u03b1 Antibody adu-1805 that blocks the sirp\u03b1-cd47 innate immune checkpoint","volume":"7","author":"Voets","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01805-9","article-title":"Imm0306, a fusion protein of cd20 mab with the cd47 binding domain of sirp\u03b1, exerts excellent cancer killing efficacy by activating both macrophages and nk cells via blockade of cd47-sirp\u03b1 Interaction and fc \u03b3r engagement by simultaneously binding to cd47 and cd20 of B cells","volume":"37","author":"Yu","year":"2023","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1710877114","article-title":"Anti-sirp\u03b1 Antibody immunotherapy enhances neutrophil and macrophage antitumor activity","volume":"114","author":"Ring","year":"2017","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00018","article-title":"Advances in anti-tumor treatments targeting the cd47\/sirp\u03b1 Axis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2022.100139","article-title":"Cd47-sirp\u03b1 Axis in cancer therapy: precise delivery of cd47-targeted therapeutics and design of anti-phagocytic drug delivery systems","volume":"15","author":"Zhu","year":"2022","journal-title":"Med Drug Discovery"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1378647","article-title":"Targeting the cd47\/sirp\u03b1 Pathway in Malignancies: recent progress, difficulties and future perspectives","volume":"14","author":"Jiang","year":"2024","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"6229","DOI":"10.3390\/cancers13246229","article-title":"Cancer therapy targeting cd47\/sirp\u03b1","volume":"13","author":"Dizman","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100070","article-title":"Cd47-sirp\u03b1-targeted therapeutics: status and prospects","volume":"13","author":"Maute","year":"2022","journal-title":"Immunooncol Technol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-1700","article-title":"Tti-621 (Sirp\u03b1fc): A cd47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding","volume":"23","author":"Petrova","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.943","article-title":"Cd47-sirp\u03b1 Blocking-based immunotherapy: current and prospective therapeutic strategies","volume":"12","author":"Bouwstra","year":"2022","journal-title":"Clin Trans Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The cd47-sirp\u03b1 Immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s12308-020-00433-5","article-title":"Evaluation of the role of cd47 in sickle cell disease","volume":"14","author":"Eldakhakhny","year":"2021","journal-title":"J Hematopathology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1348852","article-title":"Opportunities and challenges for anti-cd47 antibodies in hematological Malignancies","volume":"15","author":"Xu","year":"2024","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-3706","article-title":"Phase I study of the cd47 blocker tti-621 in patients with relapsed or refractory hematologic Malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2020.1811855","article-title":"Blockade of cd47 or sirp\u03b1: A new cancer immunotherapy","volume":"24","author":"Murata","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187262","article-title":"Tti-621 (Sirp\u03b1fc), a cd47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets","volume":"12","author":"Lin","year":"2017","journal-title":"PloS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","article-title":"Engineering strategies to enhance oncolytic viruses in cancer immunotherapy","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduction Targeted Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-024-00985-1","article-title":"Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy","volume":"19","author":"Gujar","year":"2024","journal-title":"Nat Protoc"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.09.012","article-title":"Integrating innate and adaptive immunity in oncolytic virus therapy","volume":"10","author":"DePeaux","year":"2024","journal-title":"Trends Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00866","article-title":"Oncolytic viral therapy and the immune system: A double-edged sword against cancer","volume":"9","author":"Marelli","year":"2018","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.212","article-title":"Fighting cancer with viruses: oncolytic virus therapy in China","volume":"29","author":"Wei","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.coviro.2021.03.006","article-title":"Adenovirus - a blueprint for gene delivery","volume":"48","author":"Greber","year":"2021","journal-title":"Curr Opin Virol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.3390\/ijms22052517","article-title":"Oncolytic adenoviruses for cancer therapy","volume":"22","author":"Tripodi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.707290","article-title":"Oncolytic adenovirus: prospects for cancer immunotherapy","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Microbiol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa914","article-title":"The mouse gene expression database (Gxd): 2021 update","volume":"49","author":"Baldarelli","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"B51","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-07-0912","article-title":"Tumor-associated macrophages press the angiogenic switch in breast cancer","volume":"67","author":"Lin","year":"2007","journal-title":"Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/ncb3371","article-title":"Suppression of microrna activity amplifies ifn-\u0393-induced macrophage activation and promotes anti-tumour immunity","volume":"18","author":"Baer","year":"2016","journal-title":"Nat Cell Biol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers6031670","article-title":"Tumor-associated macrophages as major players in the tumor microenvironment","volume":"6","author":"Chanmee","year":"2014","journal-title":"Cancers (Basel)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3337","article-title":"Csf-1r inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41565-018-0319-4","article-title":"In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment","volume":"14","author":"Chen","year":"2019","journal-title":"Nat Nanotechnology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1158\/1535-7163.Mct-20-0748","article-title":"Macrophages mediate the antitumor effects of the oncolytic virus hsv1716 in mammary tumors","volume":"20","author":"Kwan","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153550","article-title":"Anti-cd47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo","volume":"11","author":"Zhang","year":"2016","journal-title":"PloS One"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.04.016","article-title":"Differential fc-receptor engagement drives an anti-tumor vaccinal effect","volume":"161","author":"DiLillo","year":"2015","journal-title":"Cell"},{"key":"B59","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2015.03.004","article-title":"Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life il-2","volume":"27","author":"Zhu","year":"2015","journal-title":"Cancer Cell"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-cd47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1397248","article-title":"Anti-cd47 treatment enhances anti-tumor T-cell immunity and improves immunosuppressive environment in head and neck squamous cell carcinoma","volume":"7","author":"Wu","year":"2018","journal-title":"Oncoimmunology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3931","article-title":"Cd47 blockade triggers T cell-mediated destruction of immunogenic tumors","volume":"21","author":"Liu","year":"2015","journal-title":"Nat Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg8693","article-title":"Dual targeting of ctla-4 and cd47 on T(Reg) cells promotes immunity against solid tumors","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci Trans Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-14-1399","article-title":"Inhibition of cd47 effectively targets pancreatic cancer stem cells via dual mechanisms","volume":"21","author":"Cioffi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41377-020-00388-3","article-title":"Black phosphorus-based photothermal therapy with acd47-mediated immune checkpoint blockade for enhanced cancer immunotherapy","volume":"9","author":"Xie","year":"2020","journal-title":"Light Sci Appl"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-19-0734","article-title":"Improved antitumor efficacy of chimeric antigen receptor T cells that secrete single-domain antibody fragments","volume":"8","author":"Xie","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1158\/1078-0432.Ccr-20-2400","article-title":"Modification of extracellular matrix enhances oncolytic adenovirus immunotherapy in glioblastoma","volume":"27","author":"Kiyokawa","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/25785826.2019.1698261","article-title":"Memory T cell, exhaustion, and tumor immunity","volume":"43","author":"Ando","year":"2020","journal-title":"Immunol Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.semcancer.2021.05.019","article-title":"Optimal timing of pd-1 blockade in combination with oncolytic virus therapy","volume":"86","author":"Nguyen","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14754","article-title":"Rational combination of oncolytic vaccinia virus and pd-L1 blockade works synergistically to enhance therapeutic efficacy","volume":"8","author":"Liu","year":"2017","journal-title":"Nat Commun"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02679-5","article-title":"Tumor-selective blockade of cd47 signaling with a cd47\/pd-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity","volume":"70","author":"Wang","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202007051","article-title":"M2-like tams function reversal contributes to breast cancer eradication by combination dual immune checkpoint blockade and photothermal therapy","volume":"17","author":"Zhao","year":"2021","journal-title":"Small"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2020.1729300","article-title":"Oncolytic poxvirus cf33-hnis-\u0394f14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-pd-L1 antibody in a triple-negative breast cancer model","volume":"9","author":"Chaurasiya","year":"2020","journal-title":"Oncoimmunology"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.160","article-title":"Ctla-4 and pd-L1 checkpoint blockade enhances oncolytic measles virus therapy","volume":"22","author":"Engeland","year":"2014","journal-title":"Mol Ther"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0264-7","article-title":"A novel oncolytic virus engineered with pd-L1 scfv effectively inhibits tumor growth in a mouse model","volume":"16","author":"Wu","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-pd-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1513555\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T06:57:43Z","timestamp":1740466663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1513555\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":76,"alternative-id":["10.3389\/fimmu.2025.1513555"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1513555","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"article-number":"1513555"}}